<DOC>
	<DOCNO>NCT00149162</DOCNO>
	<brief_summary>The purpose study evaluate interest maintenance treatment interleukin-2 randomizing patient allogeneic transplanted complete remission induction consolidation chemotherapy concern event free survival .</brief_summary>
	<brief_title>Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2</brief_title>
	<detailed_description>We design open randomize study evaluate interest maintenance treatment interleukin-2 randomizing patient allogeneic transplanted complete remission induction consolidation chemotherapy concern event free survival . A total 580 patient accrue 7 year . Treatment consist subcutaneous application interleukin-2 treating patient complete remission monthly regimen 5 day 1 year receive chemotherapy consist 1 induction 3 consolidation treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Age : 0 18 year Prior untreated acute myeloid leukemia ( AML ) follow cytological type : FAB M0 , M1 , M2 , M4 , M4 eosinophil , M5 , M6 , M7 , without FAB classification show myelodysplasia ( blast &gt; 20 % ) Isolated myeloid sarcoma Achieved complete remission No HLA identical family donor , except patient ( 8 ; 21 ) No contraindication use interleukin2 Trisomy 21 Promyelocytic leukemia ( M3 ) M3 variation Secondary AML</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Controlled</keyword>
	<keyword>Multicenter</keyword>
	<keyword>International</keyword>
	<keyword>Randomized study</keyword>
	<keyword>Direct individual benefit</keyword>
	<keyword>complete remission chemotherapy</keyword>
	<keyword>non allogeneic transplant</keyword>
</DOC>